Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2022-10-26 Interim / Quarterly Rep…
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL BIOSCIENCES : Rapport financier semestriel au 30 juin 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport Financier Semestriel' (Half-Year Financial Report) for the period ending June 30, 2022. It contains detailed financial statements (Balance Sheet, Income Statement), management commentary on business activities, and notes to the financial statements. It is a comprehensive interim report, not an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H2 2022
2022-10-26 French
NFL Biosciences : Activités & Résultats du 1er semestre 2022
Earnings Release Classification · 99% confidence The document explicitly presents the "Activités & Résultats du 1er semestre 2022" (Activities & Results for the 1st half of 2022). It includes detailed financial tables comparing H1 2022 results to previous periods, discusses clinical trial progress, intellectual property updates, and partnership developments for the six-month period ending June 30, 2022. The text confirms that the semi-annual accounts were reviewed by the Statutory Auditors ("examen limité par le Commissaire aux Comptes"). This structure—a comprehensive review of operational and financial performance for a period shorter than a full year—is characteristic of an Interim/Quarterly Report. H1 2022
2022-10-25 French
NFL Biosciences: 2022 first-half business and earnings
Earnings Release Classification · 99% confidence The document explicitly states it is reporting 'results for the first half of 2022' and includes detailed financial tables comparing figures for the six months ended June 30, 2022, against previous periods. It mentions that the half-year financial statements were subject to a limited review and that the full financial report will be made available on October 26, 2022. The content is a comprehensive review of operational progress (clinical trials, partnerships) alongside the financial performance for an interim period (H1 2022). This structure aligns perfectly with the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a year. H2 2022
2022-10-25 English
NFL BIOSCIENCES CONCLUT UN PARTENARIAT AVEC THEMIS MEDICARE POUR LE DÉVELOPPEMENT DE NFL-101 EN INDE
Regulatory Filings Classification · 100% confidence The document announces a partnership between NFL Biosciences and Themis Medicare for the development of NFL-101 in India. It details the agreement, regulatory steps (IND submission to CDSCO), market size, and financial terms (royalties). This type of announcement, which details a significant business development, partnership, or strategic agreement, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, POS). It is a general corporate announcement regarding business strategy and development. Since it is not a standard regulatory filing form (like 10-K or DEF 14A) and is not a transcript, presentation, or factsheet, the most appropriate classification is the general regulatory announcement/miscellaneous category, RNS, as it is a formal communication to the market about a material event.
2022-10-05 French
NFL BIOSCIENCES PARTNERS WITH THEMIS MEDICARE FOR THE DEVELOPMENT OF NFL-101 IN INDIA
Regulatory Filings Classification · 95% confidence The document announces a strategic partnership between NFL Biosciences and Themis Medicare for the development and commercialization of NFL-101 in India. It details the submission of an IND application, clinical trial plans, financial terms (API purchase, royalties), and provides background information on both companies and the Indian tobacco market. This type of announcement, detailing a significant business development, partnership, or strategic move that is not a routine financial report (like 10-K, ER, or IR), typically falls under a general regulatory announcement or a specific category if available. Since it is a major business development announcement and not a formal financial filing, earnings release, or capital change, it best fits the general 'Regulatory Filings' (RNS) category as a significant corporate event disclosure, or potentially 'M&A Activity' (TAR) if it involved a merger, which it does not. Given the options, 'RNS' serves as the best catch-all for material, non-standard disclosures like this partnership announcement.
2022-10-05 English
NFL BIOSCIENCES BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S1 2022
Transaction in Own Shares Classification · 90% confidence The document title is "NFL BIOSCIENCES BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S1 2022" (NFL BIOSCIENCES SEMI-ANNUAL REPORT ON THE LIQUIDITY CONTRACT H1 2022). The content details the status of a liquidity contract (market making/share stabilization) as of June 30, 2022 (S1 2022), showing stock and cash balances, and transaction volumes (purchases and sales) over the first half of 2022, including a detailed daily annex. This type of report, focusing specifically on liquidity management activities and periodic updates on share transactions related to market making, does not fit neatly into standard financial reports (10-K, IR) or corporate actions (DIV, SHA). It is a specific regulatory disclosure related to market operations. Given the options, this is a specialized report. Since it is a detailed report covering a specific period (H1 2022) and is not a general announcement of a report's release, it is not RPA or RNS. It is most closely related to ongoing financial/capital activities, but none of the codes perfectly match 'Liquidity Contract Report'. However, since it details capital structure management (via share transactions/liquidity provision), and is a periodic report, it is best classified as a specialized regulatory filing that doesn't fit the primary categories. In the absence of a specific 'Liquidity Report' code, and given that it is a detailed periodic report, it is closest to an Interim/Quarterly Report (IR) or a general Regulatory Filing (RNS). Since it is a detailed report on a specific financial mechanism, and not just a general announcement, I will lean towards RNS as the most appropriate fallback for specialized, non-standard periodic disclosures, or potentially CAP if viewed as a financing/capital structure activity, but RNS is safer for non-standard disclosures. Upon review, this document is a mandatory disclosure related to the liquidity contract, which is a specific regulatory requirement in some jurisdictions. It is not a comprehensive financial report (IR/10-K). Therefore, RNS (Regulatory Filings - general/miscellaneous) is the most suitable classification for this specific, non-standard periodic disclosure.
2022-07-26 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.